Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Cotinga Pharmaceuticals Inc COTQF

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.


GREY:COTQF - Post by User

Comment by fatladysings321on Jun 24, 2017 4:19pm
341 Views
Post# 26401601

RE:Share consolidations are amateurish at best

RE:Share consolidations are amateurish at best
Well, having spent some time thinking about this, and grumbling to my wife, I think this may not be that bad. In fact, aside from the consolidation itself, and how diminished it makes ones holding seem, these are actually very positive signs for the company moving forward. First, it is very doubtful that if Coti2 were failing, that 2 promotion companies would have been brought in at the expense that that represents to the company, to promote it AT THIS POINT IN TIME. Without Coti2's sucess, promotion would be fairly ineffective. I also suspect management is aware that most equity prices fall after a reverse split as this is fairly common knowledge. So this tells me that most likely they do anticipate positive results for Coti2 sometime soon. Otherwise why do the reverse now at all? It is also true that many institutional investors and large funds are prohibited from playing the penny stocks so this will change that. It is always ALL ABOUT THE DEMAND for the shares that determines shareprice. So what we may see is a huge run on the shares after this is done and a positive interim report is completed and made public. Shareholders can aslo anticipate a partnering agreement with a big pharma partner at anytime after this report is out and at that point, the sky will be the limit on just what the value of their drug development platform is. As things progress, risk is driven to lower and lower levels. We are the only AI drug development company in North America as far as I know. So let's keep on the path and improve our proof of concept credibility and get this thing moving!  

So hang tight, and good luck folks! 
<< Previous
Bullboard Posts
Next >>